Items where authors include "Sharaf, M."

Conference or Workshop Item

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2023) P176 Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.

Tillett, W., Coates, L., Sharaf, M. et al. (7 more authors) (2022) 2142: Strong Correlation Between Short- vs Long-form Composite Measures ofPsoriatic Arthritis Disease Activity in a TNFi-IR Population Treated withGuselkumab: Data from the Phase 3b COSMOS Trial. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4248-4251.